TOLECTIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TOLECTIN (TOLECTIN).
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis.
| Metabolism | Hepatic metabolism via oxidation and conjugation; less than 1% excreted unchanged in urine; undergoes enterohepatic recirculation. |
| Excretion | Renal (90-95% as unchanged drug and metabolites, primarily glucuronide conjugates); biliary/fecal (minor, <5%). |
| Half-life | Terminal half-life approximately 5-6 hours; clinical context: dosing every 6-8 hours required due to relatively short half-life; steady-state achieved within 24-30 hours. |
| Protein binding | Approximately 99% bound, primarily to albumin. |
| Volume of Distribution | 0.15-0.25 L/kg (low, indicating limited extravascular distribution; primarily confined to plasma and interstitial fluid). |
| Bioavailability | Oral: approximately 90-95% (well absorbed); not available for parenteral routes. |
| Onset of Action | Oral: analgesic effect within 30-60 minutes; anti-inflammatory effect may take several days to weeks. |
| Duration of Action | Analgesic effect: 4-6 hours; anti-inflammatory effect: requires continuous dosing for sustained benefit; clinical notes: not suitable for once-daily dosing. |
400-600 mg orally three times daily; maximum 1.8 g/day.
| Dosage form | TABLET |
| Renal impairment | GFR 50-89 mL/min: no dose adjustment; GFR 10-49 mL/min: reduce dose by 50%; GFR <10 mL/min: avoid use. |
| Liver impairment | Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use. |
| Pediatric use | 2 years and older: 20 mg/kg/day in 3-4 divided doses; maximum 30 mg/kg/day. |
| Geriatric use | Initiate at lowest effective dose; monitor renal function and gastrointestinal tolerance; maximum 1.2 g/day. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TOLECTIN (TOLECTIN).
| Breastfeeding | Excreted into breast milk in small amounts. M/P ratio not established. Use with caution due to potential adverse effects on infant (e.g., gastrointestinal, renal). Consider alternative analgesics with better safety profiles (e.g., acetaminophen, ibuprofen). |
| Teratogenic Risk | First trimester: NSAIDs are associated with increased risk of miscarriage and congenital anomalies (cardiac, gastroschisis). Second trimester: Limited data suggest possible fetal renal dysfunction and oligohydramnios. Third trimester: Avoid due to risk of premature closure of ductus arteriosus, fetal renal impairment, oligohydramnios, and neonatal pulmonary hypertension. Tolmetin is an NSAID with similar risks. |
■ FDA Black Box Warning
NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Elderly patients and those with prior history of peptic ulcer disease or GI bleeding are at greater risk.
| Serious Effects |
Hypersensitivity to tolmetin or other NSAIDs; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
| Precautions | Risk of GI ulceration, bleeding, and perforation; cardiovascular thrombotic events (MI, stroke); renal toxicity; hypertension; fluid retention; anaphylactoid reactions; skin reactions (SJS/TEN); hepatic impairment; asthma exacerbation; hematologic effects. |
Loading safety data…
| Fetal Monitoring | Monitor fetal heart rate, amniotic fluid volume, and ductus arteriosus patency via ultrasound if used in third trimester. Assess maternal renal function and blood pressure. Watch for signs of gastrointestinal bleeding or edema. |
| Fertility Effects | May impair female fertility by inhibiting prostaglandin synthesis, affecting ovulation and implantation. Reversible upon discontinuation. Male fertility: No known significant effects. |